Skip to main content

News

October 23, 2020
umitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in…
October 23, 2020
Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address.
October 22, 2020
Highlights from the upcoming Tuesday evening CIOctober meeting session, and registration information for the complimentary session on the Clinical and Economic Value of Pushable and Detachable Coils, sponsored by Cook.
October 21, 2020
Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology
October 21, 2020
Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary site
October 21, 2020
Adaptive Clinical Trial Platform in Glioblastoma Multiforme, Expected to serve as basis for VAL-083's new drug application (NDA) submission and registration.
October 20, 2020
Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating…
October 16, 2020
Highlights from our next Tuesday evening CIOctober meeting session, and registration information for the complimentary session on Advancing the Clinical Treatment of Bone Metastases.
October 15, 2020
Technology transfer of UltraPorator to clinical sites dosing UltraCAR-T successfully completed.
October 15, 2020
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug…
Back to Top